ZLDPF - Move Aside Ozempic WeGovy: Denmark's New Drug Just Showed Positive Results For Weightloss | Benzinga
Danish biotech company Zealand Pharma A/S (OTC:ZLDPF) has announced encouraging topline results from a Phase 1b multiple ascending dose (MAD) trial of its weight management drug, petrelintide. The trial results were released on Thursday and comes at a time when the weightloss drug market is experiencing domination of another Danish pharmaceutical company Novo Nordisk (NYSE:NVO) (OTC:NONOF) which produces Ozempic and WeGovy.
What Happened: As per the official press release, the 16-week trial aimed to evaluate the safety, tolerability, and clinical effects of petrelintide. The drug, designed for weight management, demonstrated “significant and clinically meaningful reductions in body weight with a very favorable tolerability profile,” ...